Department of Internal Medicine, Chung-Ang University College of Medicine, Republic of Korea.
J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1.
The clinical effect of probiotics on irritable bowel syndrome (IBS) is still controversial.
We aimed to evaluate the effects of a probiotic mixture on IBS symptoms and the composition of fecal microbiota in patients with diarrhea-dominant IBS (D-IBS).
Fifty patients with D-IBS were randomized into placebo or probiotic mixture (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10 CFU) groups. Treatment was taken daily for 8 weeks. The primary outcome was adequate relief (AR) of overall IBS symptoms, which was assessed weekly for 10 weeks. A responder was defined as a patient who experienced AR for at least half of the 10-week study period. Secondary outcomes included the effects on individual symptoms, stool parameters, and IBS quality of life. The fecal flora compositions were analyzed by polymerase chain reaction denaturing gradient gel electrophoresis (DGGE).
The proportion of AR was consistently higher in the probiotics group than in the placebo group throughout the 10-week period (P<0.05). The proportion of responders was significantly higher in the probiotics group than in the placebo group (48% vs. 12%, P=0.01). Stool consistency improved significantly in the probiotics group compared with the placebo group. Percent changes in individual symptom scores were similar in the 2 groups, but IBS quality of life improvement tended to be higher in the probiotics group. Comparison of denaturing gradient gel electrophoresis profiles of fecal flora showed that the concordance rate between bacterial compositions before and after treatment was significantly higher in the probiotics group than in the placebo group (69.5% vs. 56.5%, P=0.005).
The probiotic mixture was effective in providing AR of overall IBS symptoms and improvement of stool consistency in D-IBS patients, although it had no significant effect on individual symptoms. The therapeutic effect of probiotics is associated with the stabilization of intestinal microbiota.
益生菌对肠易激综合征(IBS)的临床疗效仍存在争议。
我们旨在评估益生菌混合物对腹泻型肠易激综合征(D-IBS)患者的 IBS 症状和粪便微生物群落组成的影响。
50 例 D-IBS 患者随机分为安慰剂或益生菌混合物(嗜酸乳杆菌、植物乳杆菌、鼠李糖乳杆菌、短双歧杆菌、乳双歧杆菌、长双歧杆菌和嗜热链球菌 1.0×10 CFU)组。治疗组每天服用,持续 8 周。主要结局是整体 IBS 症状的充分缓解(AR),在 10 周的研究期间每周评估一次。应答者定义为在 10 周研究期间至少有一半时间经历 AR 的患者。次要结局包括对个体症状、粪便参数和 IBS 生活质量的影响。通过聚合酶链反应变性梯度凝胶电泳(DGGE)分析粪便菌群组成。
在整个 10 周期间,益生菌组的 AR 比例始终高于安慰剂组(P<0.05)。益生菌组的应答者比例明显高于安慰剂组(48%比 12%,P=0.01)。与安慰剂组相比,益生菌组的粪便稠度明显改善。两组患者的个体症状评分的百分比变化相似,但益生菌组的 IBS 生活质量改善趋势更高。粪便菌群 DGGE 图谱比较显示,治疗前后细菌组成的一致性在益生菌组明显高于安慰剂组(69.5%比 56.5%,P=0.005)。
益生菌混合物可有效提供 D-IBS 患者 IBS 症状的 AR 和粪便稠度的改善,尽管对个体症状没有显著影响。益生菌的治疗效果与肠道微生物群的稳定有关。